Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22509292 | 0.87 | KDM1A (0.51) | KDM1ACACNA1BFOLH1 | |
| SCHEMBL21196892 | 0.87 | KDM1A (0.51) | KDM1ACACNA1BFOLH1 | |
| SCHEMBL20857557 | 0.83 | KDM1A (0.39) | KDM1A | |
| SCHEMBL21842544 | 0.81 | KDM1A (0.38) | KDM1A | |
| SCHEMBL26431181 | 0.81 | KDM1A (0.51) | KDM1AKISS1R | |
| SCHEMBL26204940 | 0.79 | KDM1A (0.46) | KDM1A | |
| SCHEMBL22086060 | 0.78 | KDM1A (0.49) | KDM1AKISS1R | |
| SCHEMBL24641589 | 0.78 | SMN1; SMN2 (0.37) | KISS1RCACNA1BFOLH1KDM4EMAPK1 | |
| SCHEMBL16622177 | 0.78 | MEN1 (0.55) | KISS1R | |
| SCHEMBL18030908 | 0.77 | KDM1A (0.51) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052121-B1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-10967042-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210007987-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10813884-B2 | WNT compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200289609-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200040048-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9505804-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160310424-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| US-20160193283-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2016-07-07 | — | — | US | disclosed |
| WO-2015051122-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210007987-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | WNT3A, CTNNBL1, WNT1 | KDM1A 4471/4885KISS1R 4586/4885CACNA1B 3451/4885 |
| US-20160193283-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | TP53, TP53BP1, MDM2 | KDM1A 4466/4885KISS1R 3564/4885CACNA1B 4735/4885 |
| US-10813884-B2 | WNT compositions and methods for purification | WNT3A, CTNNBL1, WNT1 | KDM1A 4471/4885KISS1R 4586/4885CACNA1B 3451/4885 |
| US-20200040048-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | FLT3, BID, GRPR | KDM1A 4800/4885KISS1R 2336/4885CACNA1B 4805/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | KDM1A 4829/4885KISS1R 1813/4885CACNA1B 4806/4885 |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | KDM1A 4515/4885KISS1R 101/4885CACNA1B 4483/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | KDM1A 3908/4885KISS1R 3182/4885CACNA1B 4513/4885 |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | KDM1A 4848/4885KISS1R 2699/4885CACNA1B 4832/4885 |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | KDM1A 3860/4885KISS1R 2892/4885CACNA1B 4763/4885 |
| US-20200289609-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | MPL, MUC1, FLT3 | KDM1A 4617/4885KISS1R 883/4885CACNA1B 4791/4885 |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | FLT3, BID, GRPR | KDM1A 4800/4885KISS1R 2336/4885CACNA1B 4805/4885 |
| US-20160310424-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | WNT3A, CTNNBL1, WNT1 | KDM1A 4471/4885KISS1R 4586/4885CACNA1B 3451/4885 |
| US-10967042-B2 | Peptidomimetic macrocycles | TP53, MDM2, MDM4 | KDM1A 3860/4885KISS1R 2892/4885CACNA1B 4763/4885 |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | KDM1A 4535/4885KISS1R 486/4885CACNA1B 4572/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | KDM1A 4770/4885KISS1R 654/4885CACNA1B 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.